- Home
- CEE vs TTRX Comparison
CEE vs TTRX Comparison
Compare CEE & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | TTRX |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.3M | 116.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CEE | TTRX |
|---|---|---|
| Price | $19.21 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 22.0K | ★ 41.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.80 | $2.57 |
| 52 Week High | $10.32 | $26.50 |
Technical Indicators
Market Signals| Indicator | CEE | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 61.53 | N/A |
| Support Level | $19.10 | N/A |
| Resistance Level | $19.50 | N/A |
| Average True Range (ATR) | 0.56 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 89.20 | 0.00 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.